No one-trick pony – advancing a novel platform-based CNS company
AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity.
We update our rating to Outperform and raise the target price to SEK 16 per share, corresponding to an equity value of approximately SEK 600m non-diluted, derived from risk-adjusted DCF valuation of ACD856 and ACD440.read more
When genomics and proteomics converge, Immunovia will probably be snatched up
By being at the forefront of proteomics-based technology, nearing launch of the first to market, outstandingly accurate blood-based test for early detection of pancreatic cancer, we see Immunovia as an apparent strategic target for acquisition.
We maintain the Outperform rating and raise the target price to 300 SEK per share, corresponding to an equity value of SEK 6.8 bn non-diluted, derived from a DCF valuation of the opportunity in pancreatic cancer.read more
Vator Securities rådger Xintela i 37 MSEK företrädesemission
Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 37 miljoner.
Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.read more
Vator Securities advises LIDDS on 59,3 MSEK Directed and Rights Issue
Vator Securities acts as Financial Advisor in connection with the transaction raising SEK 59,3 million.
LIDDS is a Swedish-based pharmaceutical company which develops new innovative pharmaceutical products with its proprietary drug delivery technology NanoZolid®.read more